Abstract:Purpose The programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) expression correlate with the immunotherapeutic response rate. The sensitive and non-invasive imaging of immune checkpoint biomarkers is favorable for the accurate detection and characterization, image-guided immunotherapy in cancer precision medicine. Magnetic particle imaging (MPI), as a novel and emerging imaging modality, possesses the advantages of high sensitivity, no image depth limitation, positive contrast, and absence of radiation. Hence, in this study, we performed the pioneer investigation of monitoring PD-L1 expression using MPI and the MPI-guided immunotherapy. Methods We developed anti-PD-L1 antibody (aPDL1)-conjugated magnetic fluorescent hybrid nanoparticles (MFNPs-aPDL1) and utilized MPI in combination with fluorescence imaging (FMI) to dynamically monitor and quantify PD-L1 expression in various tumors with different PD-L1 expression levels. The ex vivo real-time polymerase chain reaction (qPCR), western blotting, and immunofluorescence staining analysis were further performed to validate the in vivo imaging observation. Moreover, the MPI was further performed for the guidance of immunotherapy. Results Our data showed that PD-L1 expression can be specifically and sensitively monitored and quantified using MPI and FMI imaging methods, which were validated by ex vivo qPCR and western blotting analysis. In addition, MPI-guided PD-L1 immunotherapy can enhance the effectiveness of cancer immunotherapy. Conclusion To our best knowledge, this is the pioneer study to utilize MPI in combination with a newly developed MFNPs-aPDL1 imaging probe to dynamically visualize and quantify PD-L1 expression in tumor microenvironment. This imaging strategy may facilitate the clinical optimization of immunotherapy management.

Application of Molecular Imaging in Immune Checkpoints Therapy: from Response Assessment to Prognosis Prediction.

Positron Emission Tomography Molecular Imaging to Monitor Anti-Tumor Systemic Response for Immune Checkpoint Inhibitor Therapy

The role of radiotherapy in tumor immunity and the potential of PET/CT in detecting the expression of PD-1/PD-L1

Advances in molecular imaging of immune checkpoint targets in malignancies: current and future prospect

Molecular imaging to support cancer immunotherapy

Tumor Immune Checkpoints and Their Associated Inhibitors

Applications of CT-based radiomics for the prediction of immune checkpoint markers and immunotherapeutic outcomes in non-small cell lung cancer

The Role of PET Molecular Imaging in Immune Checkpoint Inhibitor Therapy in Lung Cancer: Precision Medicine and Visual Monitoring.

[Overview of Multiplex Immunohistochemistry and Immunofluorescence Techniques in the Lung Cancer Immunotherapy].

Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives

[Advances in Imaging-Based Evaluation of Solid Tumors Treated With Immune Checkpoint Inhibitors]

Fluorescence Imaging of Tumor Immune Contexture in Immune Checkpoint Blockade Therapy.

Advances and prospects of biomarkers for immune checkpoint inhibitors

Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts

Predictive Biomarkers for Tumor Immune Checkpoint Blockade

Sensitive and Quantitative in Vivo Analysis of PD-L1 Using Magnetic Particle Imaging and Imaging-Guided Immunotherapy

Potentials of Non-Invasive 18F-FDG PET/CT in Immunotherapy Prediction for Non–Small Cell Lung Cancer

Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors

ImmunoPET provides a novel way to visualize the CD103+ tissue-resident memory T cell to predict the response of immune checkpoint inhibitors

Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis

Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1